title: [Fosfomycin in the treatment of recurrent tract infections in type 2 diabetic patients].
abstract: The aim of this study was to evaluate the efficacy of chronic therapy with fosfomycin trometamol (TF) in the treatment and prevention of recurrent, uncomplicated urinary tract infections (NIDDM) in type 2 diabetic women.
  
  
  METHODS
  The study comprised 45 type 2 diabetes women aged 50-70 years. All patients enrolled into the study suffered from the NIDDM presented with clinical signs of uroinfection and positive urine culture with bacterial uropathogen sensitive to TF. Study period lasted 12 months and during the first 9 months patients were treated with TF. The patients remained under regular medical supervision in diabetic outpatient clinic every 3 months. Efficacy of treatment was proved when both clinical cure and uropathogen eradication were achieved in 3, 6, 9 or 12th month from the study beginning.
  
  
  RESULTS
  The difference in efficiency of fosfomycin treatment after 3 months of the study duration in comparison with duration before study beginning was statistically different (p<0.001). The differences in efficiency of fosfomycin treatment after 6 months of study duration in comparison with time before 3 months were statistically different (p=0.03). There was not statistically differences in efficiency of fosfomycin treatment between the 6th and 9th month of study duration (NS).
  
  
  CONCLUSIONS
  Fosfomycin is the safe and effective antimicrobial method to cure and prevent NIDDM.
authors.affiliation: Klinika Kardiologii Interwencyjnej, Kardiodiabetologii i Rehabilitacji Kardiologicznej, USK Nr 2 im. WAM Uniwersytet Medyczny w Lodzi. mozdzanm@poczta.onet.pl
authors.forename: Michał
authors.initials: M
authors.lastname: Mozdzan
authors.forename: Jerzy
authors.initials: J
authors.lastname: Loba
authors.forename: Jan
authors.initials: J
authors.lastname: Ruxer
authors.forename: Leszek
authors.initials: L
authors.lastname: Markuszewski
mesh_terms: D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D005260:Female; D005578:Fosfomycin / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D016896:Treatment Outcome; D014552:Urinary Tract Infections / Q000188:drug therapy*
chemical_list: D000900:Anti-Bacterial Agents; D005578:Fosfomycin